Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors

Ahmad, Anas; Rashid, Summya; Chaudhary, Anis Ahmad; Alawam, Abdullah S.; Alghonaim, Mohammad Ibrahim; Raza, Syed Shadab; Khan, Rehan

doi:10.1016/j.semcancer.2023.01.002

Cited by 7 publications

(1 citation statement)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanomedicine is a novel unique branch of medicine using nanosize technology for exploration of underlying mechanisms of disease development and progression and for the prevention, diagnosis and therapy of various diseases (de Lazaro and Mooney, 2021 ;Stater et al, 2021). Nanomedicine has been used for cancer diagnosis and therapy via merging the physical, biological, chemical and digital technologies together (Ahmad et al, 2023;Li et al, 2023). In recent years, nanomedicine has exhibited a potent effect in immunotherapy for cancer patients (Irvine and Dane, 2020;Guo et al, 2022b;Wang et al, 2022b;Yang et al, 2023).…”

Section: Nanomedicinementioning

confidence: 99%

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

et al. 2023

View full text Add to dashboard Cite

Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy leads to adaptive immune resistance and displays resistance to PD-1/PD-L1 blockade in lung cancer, leading to less immune response of lung cancer patients. Tumor microenvironment (TME) is an integral tumor microenvironment, which is involved in immunotherapy resistance. Nanomedicine has been used to enhance the immunotherapy in lung cancer. In this review article, we described the association between TME and immunotherapy in lung cancer. We also highlighted the importance of TME in immunotherapy in lung cancer. Moreover, we discussed how nanoparticles are involved in regulation of TME to improve the efficacy of immunotherapy, including Nanomedicine SGT-53, AZD1080, Nanomodulator NRF2, Cisplatin nanoparticles, Au@PG, DPAICP@ME, SPIO NP@M-P, NBTXR3 nanoparticles, ARAC nanoparticles, Nano-DOX, MS NPs, Nab-paclitaxel, GNPs-hPD-L1 siRNA. Furthermore, we concluded that targeting TME by nanoparticles could be helpful to overcome resistance to PD-1/PD-L1 blockade in lung cancer.

show abstract